Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.

Literature DB >> 18285479

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.

Eric Nuermberger¹, Sandeep Tyagi, Rokeya Tasneen, Kathy N Williams, Deepak Almeida, Ian Rosenthal, Jacques H Grosset.

Abstract

PA-824 is a nitroimidazo-oxazine in clinical testing for the treatment of tuberculosis. We report that the novel combination of PA-824, moxifloxacin, and pyrazinamide cured mice more rapidly than the first-line regimen of rifampin, isoniazid, and pyrazinamide. If applicable to humans, regimens containing this combination may radically shorten the treatment of multidrug-resistant tuberculosis.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 18285479 PMCID： PMC2292539 DOI： 10.1128/AAC.00074-08

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

7 in total

1. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps.

Authors: R J O'Brien; P P Nunn
Journal: Am J Respir Crit Care Med Date: 2001-04 Impact factor: 21.405

2. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.

Authors: Eric Nuermberger; Ian Rosenthal; Sandeep Tyagi; Kathy N Williams; Deepak Almeida; Charles A Peloquin; William R Bishai; Jacques H Grosset
Journal: Antimicrob Agents Chemother Date: 2006-08 Impact factor: 5.191

3. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Authors: C K Stover; P Warrener; D R VanDevanter; D R Sherman; T M Arain; M H Langhorne; S W Anderson; J A Towell; Y Yuan; D N McMurray; B N Kreiswirth; C E Barry; W R Baker
Journal: Nature Date: 2000-06-22 Impact factor: 49.962

4. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Authors: Sandeep Tyagi; E Nuermberger; T Yoshimatsu; K Williams; I Rosenthal; N Lounis; W Bishai; J Grosset
Journal: Antimicrob Agents Chemother Date: 2005-06 Impact factor: 5.191

5. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.

Authors: Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Richard J O'Brien; Andrew N Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset
Journal: Am J Respir Crit Care Med Date: 2003-10-24 Impact factor: 21.405

6. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.

Authors: Eric L Nuermberger; Tetsuyuki Yoshimatsu; Sandeep Tyagi; Kathy Williams; Ian Rosenthal; Richard J O'Brien; Andrew A Vernon; Richard E Chaisson; William R Bishai; Jacques H Grosset
Journal: Am J Respir Crit Care Med Date: 2004-08-11 Impact factor: 21.405

7. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Authors: Makoto Matsumoto; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Hidetsugu Tsubouchi; Hirofumi Sasaki; Yoshihiko Shimokawa; Makoto Komatsu
Journal: PLoS Med Date: 2006-11 Impact factor: 11.069

7 in total

78 in total

Review 1. The chemical biology of new drugs in the development for tuberculosis.

Authors: Clifton E Barry; John S Blanchard
Journal: Curr Opin Chem Biol Date: 2010-05-07 Impact factor: 8.822

2. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.

Authors: Rokeya Tasneen; Si-Yang Li; Charles A Peloquin; Dinesh Taylor; Kathy N Williams; Koen Andries; Khisimuzi E Mdluli; Eric L Nuermberger
Journal: Antimicrob Agents Chemother Date: 2011-09-19 Impact factor: 5.191

3. New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.

Authors: Marcus B Conde; José R Lapa E Silva
Journal: Drug Dev Res Date: 2011-09 Impact factor: 4.360

4. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.

Authors: Andreas H Diacon; Rodney Dawson; Madeleine Hanekom; Kim Narunsky; Stefan J Maritz; Amour Venter; Peter R Donald; Christo van Niekerk; Karl Whitney; Doris J Rouse; Martino W Laurenzi; Ann M Ginsberg; Melvin K Spigelman
Journal: Antimicrob Agents Chemother Date: 2010-05-24 Impact factor: 5.191

5. The anti-trypanosome drug fexinidazole shows potential for treating visceral leishmaniasis.

Authors: Susan Wyllie; Stephen Patterson; Laste Stojanovski; Frederick R C Simeons; Suzanne Norval; Robert Kime; Kevin D Read; Alan H Fairlamb
Journal: Sci Transl Med Date: 2012-02-01 Impact factor: 17.956

6. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis.

Authors: Wanliang Shi; Xuelian Zhang; Xin Jiang; Haiming Yuan; Jong Seok Lee; Clifton E Barry; Honghai Wang; Wenhong Zhang; Ying Zhang
Journal: Science Date: 2011-08-11 Impact factor: 47.728

7. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).

Authors: Joseph Cherian; Inhee Choi; Amit Nayyar; Ujjini H Manjunatha; Tathagata Mukherjee; Yong Sok Lee; Helena I Boshoff; Ramandeep Singh; Young Hwan Ha; Michael Goodwin; Suresh B Lakshminarayana; Pornwaratt Niyomrattanakit; Jan Jiricek; Sindhu Ravindran; Thomas Dick; Thomas H Keller; Veronique Dartois; Clifton E Barry
Journal: J Med Chem Date: 2011-07-26 Impact factor: 7.446